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Rotavirus vaccination started in Slovenia in 2007 on a voluntarily basis. The vaccination rate is relatively
low (up to 27%) and no increasing trend is observed. We present rotavirus genotype distribution among
children hospitalized for rotavirus gastroenteritis in Slovenia. Eight consecutive rotavirus seasons were
followed, from 2005/06 to 2012/13, and 113 strains of the most common rotavirus genotypes were
randomly selected for molecular characterization of rotavirus VP7 and VP4 (VP8⁄) genome segments.
During the vaccine introduction period, from 2007 to 2013, rotavirus genotype prevalences changed, with
G1P[8] decreasing from 74.1% to 8.7% between 2007/08 and 2010/11 seasons, replaced by G4P[8] and
G2P[4], with up to 52.0% prevalence. Comparable analysis of VP7 and VP8⁄ genome fragments within
G1P[8] genotype lineages revealed considerable differences for rotavirus strains circulating before and
during the vaccination period. The G1P[8] rotavirus strains from the pre-vaccination period clustered
in a phylogenetic tree within Rotarix-like VP7 and VP8⁄ lineages. However, since 2007, the majority
of G1P[8] strains have shifted to distant genetic lineages with lower nucleotide (88.1–94.0% for VP7
and 86.6–91.1% for VP8⁄) and amino acid (93.8–95.2% for VP7 and 85.3–94.6% for VP8⁄) identities to
the vaccine Rotarix strain. This change also resulted in a different deduced amino acid proﬁle at the
major VP7 and VP8⁄ antigenic epitopes.
 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction In rotavirus pathogenesis, the outer capsid glycoprotein VP7Group A rotaviruses are the leading cause of acute
gastroenteritis in children worldwide (Parashar et al., 2006).
Although hygiene is a very important preventive measure against
the disease, it does not provide an efﬁcient tool for the termination
of virus transmission and lowering the disease burden in society.
This is evident from comparing morbidity data for developing
and industrialized countries. The incidence of rotavirus disease in
industrialized countries without rotavirus vaccination is still high,
which contributes signiﬁcantly to the hospitalization rate and phy-
sician visits of young children. High direct and indirect costs
related to the disease thus justify the development and use of an
effective rotavirus vaccine (Parashar et al., 2006).and the protease sensitive protein VP4 have a speciﬁc role in the
early steps of the virus replication cycle. They express antigenic
properties of rotaviruses and possess speciﬁc neutralization
epitopes (Trask et al., 2012). Neutralizing antibodies can either
physically disable virus attachment to the receptor or stabilize
the outer layer, thus inhibiting conformational changes needed
for rotavirus entry into the cell and uncoating of the outer capsid
layer (Aoki et al., 2009). Rotavirus infection can be terminated dur-
ing these early steps if speciﬁc neutralizing antibodies are present.
The genetic characteristics of VP7 and VP4 rotavirus genes are
of signiﬁcant interest for rotavirus molecular epidemiology, deter-
mining the dual genotype classiﬁcation (Gentsch et al., 1992;
Gouvea et al., 1990). Genotypes G (for VP7) and genotypes P (for
VP4) are assigned to each rotavirus strain based on nucleotide
sequence identities. A similar genotyping protocol has also been
proposed for other genome segments, comprising the whole gen-
ome classiﬁcation proposed by the Rotavirus Classiﬁcation Work-
ing Group (RCWG) (Matthijnssens et al., 2011, 2008). To date, 27
G and 37 P genotypes have been described, with more than 60
G–P combinations found, of which only 10 have been detected in
humans (Matthijnssens and Van Ranst, 2012; Santos and
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combinations that are the most prevalent in childhood diarrhea:
G1P[8], G2P[4], G3P[8], G4P[8] and G9P[8] (Banyai et al., 2012).
In the 1990s, G12P[8] appeared and became the sixth most
common genotype in some geographical areas (Matthijnssens
et al., 2010).
Zoonotic potential and interspecies transmission of group A
rotaviruses are high, which was already noted in early research
steps of rotavirus epidemiology in the 1980s (Cook et al., 2004).
However, only a small proportion of zoonotic transmitted strains
cause major outbreaks or spread quickly within the human
population. Rather, there are sporadic cases with no major impact
on the rotavirus epidemiology (Gentsch et al., 2005; Martella et al.,
2010; Papp et al., 2013; Steyer et al., 2008). Nevertheless, following
rotavirus epidemiology is of high importance, also for detecting
these zoonotic strains, since they could undergo genome reassort-
ment and inﬂuence the genotype pattern over a longer time scale,
as was shown in the case of G9P[8] (Iturriza-Gomara et al., 2000;
Matthijnssens et al., 2010).
Following rotavirus molecular epidemiology has been an espe-
cially high priority in the last seven years since two rotavirus vac-
cines, Rotarix (GlaxoSmithKline) and RotaTeq (Merck Sharp &
Dohme), were introduced and have been in use (Lopman et al.,
2012). Some countries have included this vaccine in the national
vaccination program and achieved very good vaccination coverage
in infants. In those countries, rotavirus incidence and hospitaliza-
tion rates for rotavirus gastroenteritis have decreased signiﬁcantly
(Buttery et al., 2011; Dennehy, 2012; Msimang et al., 2013; Payne
et al., 2013; Standaert et al., 2013; Vesikari et al., 2013). The effec-
tiveness of the two rotavirus vaccines was conﬁrmed in large pre-
licensure clinical trials and they showed good protection for the
most common rotavirus genotypes (Ruiz-Palacios et al., 2006;
Vesikari et al., 2006). In the post-licensure period, rotavirus strain
surveillance studies are on-going in order to collect epidemiologi-
cal data on vaccine inﬂuence on rotavirus molecular epidemiology
and to ensure that the selective pressure of the vaccine will not
result in ﬁltration of vaccine escape mutants (Jain et al., 2014;
Leite et al., 2008; Lopman et al., 2012; Zeller et al., 2010).
In our study, archived and current circulating rotavirus strains
were selected for comparative molecular analysis of the most
common genotype strains in Slovenia during eight consecutive
rotavirus seasons (2005/06–2012/13). Phylogenetic clustering
and a detailed analysis of amino acid residues at the antigenic
epitopes were carried out to explain genotype variation after the
vaccine introduction period in Slovenia.2. Materials and methods
2.1. Sample collection
Stool samples were collected mainly from hospitalized children
presenting with acute gastroenteritis. Unfortunately, clinical data
were not available for most of the children since this was a retro-
spective study and archived stool samples were analyzed. Stool
samples from conﬁrmed rotavirus infections were collected in
regional laboratories from six of eight healthcare regions in
Slovenia and sent to the Institute of Microbiology and Immunol-
ogy, Faculty of Medicine, University of Ljubljana. Stool samples
were stored at 20 C prior to genotyping and molecular analysis
of rotavirus strains. In the study period of the 8 consecutive rotavi-
rus seasons, from 2005/06 to 2012/13, a total of 3227 rotavirus
strains were analyzed.
A 10% stool suspension was prepared in 0.2 M PBS (pH value
7.4) and centrifuged for 5 min at 1600g for clariﬁcation. An
aliquot of 200 ll supernatant was used further for total nucleicacid extraction with an iPrep™ PureLink Virus Kit (Life Technolo-
gies, Invitrogen Division, Carlsbad, CA). Extracted nucleic acid was
stored at 80 C until further use for genotyping.
2.2. RT-PCR and genotyping
For rotavirus genotyping, VP7 and VP8⁄ segments were initially
ampliﬁed, using VP7-F/R and VP4-F/R primer pairs, adopted from
the EuroRotaNet guidelines (www.eurorota.net) (Iturriza-Gomara
et al., 2011). Ampliﬁcation was carried out using the Superscript
II One-step RT-PCR system (Life Technologies, Invitrogen Division).
The RT and PCR conditions were set up according to the manufac-
turer’s instructions, except for the annealing temperatures, which
were 52 C for VP7 and 50 C for VP8⁄, as proposed by the EuroRo-
taNet guidelines. For genotyping, multiplex PCR was used sepa-
rately for genotypes G (for the VP7 segment) and genotypes P
(for the VP8⁄ segment). For VP7, G1–G4, G8–G10, G12 and for
VP4, P[4], P[6], P[8], P[9], P[10], P[11], type speciﬁc primers were
included in a multiplex reaction (Iturriza-Gomara et al., 2011),
using the Tﬁ polymerase enzyme system (Life Technologies, Invit-
rogen Division). Genotypes were conﬁrmed based on the PCR
ampliﬁed fragments, separated by 1.5% agarose gel electrophoresis.
2.3. Sequencing and NA analysis
The period of our study included rotavirus consecutive seasons
2005/06–2012/13. In each season, up to 20 rotavirus strains were
selected with a representative number of genotypes: G1P[8],
G2P[4], G4P[8] and G9P[8]. However, there were not enough
strains in each season to reach this target for some genotypes. In
total, 113 strains were analyzed: 31 G1P[8] (2 in 2005, 4 in each
of 2006, 2007 and 2009–2012 and 5 in 2008); 21 G2P[4] (3 in
2007, 6 in each of 2008 and 2011, 1 in 2009, 2 in 2010, 3 in
2012); 33 G4P[8] (5 in each of 2005 and 2009, 4 in each of 2006,
2008 and 2010–2012, 3 in 2007), 28 G9P[8] (6 in 2005, 5 in
2012, 4 in 2006, 3 in each of 2007, 2009 and 2010, 2 in each of
2008 and 201).
For each rotavirus strain, VP7 and VP8⁄ ampliﬁed fragments
were puriﬁed using the Exo I/FastAP™ enzyme system (Thermo
Fischer Scientiﬁc, Waltham, MA) (Werle et al., 1994). All genome
fragments were directly sequenced with the initial PCR primers
used in the ﬁrst round RT-PCR of the VP7 and VP8⁄ ampliﬁcation
reaction. An ABI PRISM BigDyeTM 3.1 terminator Cycle Sequencing
Ready Reaction Kit (Applied Biosystems) was used for the sequenc-
ing reaction in a 20 ll reaction and puriﬁed with a BigDye Xtermi-
nator™ puriﬁcation kit (Applied Biosystems). Sequence data were
generated in an ABI 3500 Genetic Analyzer (Applied Biosystems).
Nucleotide sequences were aligned and assembled in CLC Main
Workbench 6.9 software (CLC Bio, Aarhus, Denmark). Alignment
and the construction of a Neighbor-Joining phylogenetic tree was
performed in the MEGA 5.2 software package (Tamura et al., 2011).
Nucleotide and amino acid sequences obtained in this study
were deposited in GenBank under accession numbers KJ432637–
KJ432862.
2.4. Rotavirus disease burden and vaccination coverage in Slovenia
Epidemiological data of rotavirus infections were collected for
children in the age group of 0–6 years for each of the analyzed sea-
son to estimate the eventual reduction of rotavirus disease. The
overall rotavirus incidence was calculated based on the total
reported cases of rotavirus infections (hospitalized and outpa-
tients) and the hospitalization incidence was calculated according
to the reported hospitalized cases of rotavirus diarrhea. The inci-
dences were calculated for the total population of children in the
age group 0–6 years.
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lated based on the total number of life births in a speciﬁc year,
divided by the number of fully vaccinated children in the same
year.
Ofﬁcial data were obtained from the Statistical Ofﬁce of the
Republic of Slovenia (http://www.stat.si/eng/index.asp) and
National Institute of Public Health of the Republic of Slovenia
(http://www.ivz.si/).Fig. 1. (A) Prevalence of rotavirus G–P genotypes throughout the study period of eight con
children 0–1 year of age in Slovenia; (B) presentation of rotavirus disease burden in Sl
rotavirus cases per 100,000 children in the age group of 0–6 years.3. Results
3.1. Rotavirus genotype prevalence and vaccination coverage
In the 2005/06–2012/13 rotavirus seasons, genotypes G1P[8],
G2P[4], G4P[8] and G9P[8] represented 84.2–96.2% of all genotype
strains detected in our study. Genotype G3P[8] was detected
rarely, the highest prevalence was noted in 2006/07 and 2012/13secutive seasons 2005/06–2012/13 and the dynamic of vaccination coverage among
ovenia, showing the incidence of rotavirus cases and the incidence of hospitalized
416 A. Steyer et al. / Infection, Genetics and Evolution 28 (2014) 413–425seasons with 5.7% and did not exceed a 1% prevalence in other sea-
sons of our study period. Similarly, G12P[8] was detected in up to
3.5% (Fig. 1A).
Although the most prevalent genotypes were as expected,
G1P[8], G2P[4], G4P[8] and G9P[8], the genotype prevalence proﬁle
changed drastically over the study period. G1P[8] was the most
prevalent genotype in the 2005/06–2008/09 seasons. However,
G4P[8] increased slightly in the 2008/09 season (29.7%) but
presented as the most common genotype in the next season,
2009/10, with 52.1% and G1P[8] was found only in 31.6%. BothA
Fig. 2. Phylogenetic analysis of the VP7 nucleotide sequence of Slovenian rotavirus stra
GenBank (A) G1 genotype VP7 sequences; (B) G2 genotype VP7 sequences; (C) G4 genot
trees were constructed with the Mega 5.2 software package, using the Kimura-2 parame
code for Slovenia.prevalences, for G1P[8] and G4P[8], decreased in 2010/11 and, in
contrast, G2P[4] became the most prevalent type detected in
41.6% of tested strains and also remained high in the 2011/12
season (36.2%) (Fig. 1A).
Plotting the vaccination coverage in Slovenia to the genotype
prevalence graph, a correlation of a sharp decrease of G1P[8]
prevalence and increase of vaccination coverage was observed.
Vaccination started in Slovenia in January 2007 but only Rotarix
was available in this year and the coverage was 5.5% among chil-
dren 0–1 years of age. RotaTeq was introduced only at the endins, Rotarix and RotaTeq vaccine strains and lineage-speciﬁc strains obtained from
ype VP7 sequences; (D) G9 genotype VP7 sequences. Neighbor-joining phylogenetic
ter method with bootstrapping of 1000 replicates. SVN – a unique 3-letter country
BFig. 2 (continued)
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with 26.9%, and decreased slowly each year, down to 24.5% in
2011 and 24.1% in 2012 (Fig. 1A).3.2. Rotavirus disease burden
The rotavirus incidence among children 0–6 years was between
1542.01/100,000 and 1627.76/100,000 for the seasons 2005/06 to
2007/08. After this period, the incidence started to decline from
1093.94/100,000 to as low as 603.20/100,000 (Fig. 1B). The reduc-
tion was noted also for the incidence of rotavirus hospitalizations
among children 0–6 years, ranging between 705.43/100,000 in
2006/07 and 1303.29/100,000 in 2007/08, followed by the
decreased level from 717.08/100,000 in 2008/09 to 37.42/
100,000 in 2012/13. Both data showed the reduction trend of rota-
virus disease burden together with increasing vaccine coverage in
the target population.3.3. Molecular characteristics of rotavirus strains in VP7 and VP4
(VP8⁄)
For this study, G1P[8], G2P[4], G4P[8] and G9P[8] rotavirus
strains were selected for detailed molecular analysis of the
outermost proteins, glycoprotein VP7 and the VP8⁄ fragment of
VP4, both of them carrying the serotype-speciﬁc antigen epitopes
and neutralization sites determined in previous studies (Aoki
et al., 2009; Dormitzer et al., 2002).
VP7 of G1P[8] strains. As shown in Fig. 2A, the VP7 phylogenetic
analysis of G1 rotavirus strains revealed two separate groups. The
ﬁrst group clusters into lineage II, in which the Rotarix G1P[8]
vaccine strain was also found. However, with a bootstrap of 84,
Slovenian strains grouped into a different branch than the vaccine
strain. The nucleotide sequence identity between the Rotarix
vaccine strain and Slovenian strains within lineage II was in the
range of 97.5–97.9% (Table 1). Comparing the deduced amino acid
sequences, this identity was 97.3–97.8%. Slovenian G1 strains
CFig. 2 (continued)
418 A. Steyer et al. / Infection, Genetics and Evolution 28 (2014) 413–425within lineage II of VP7 are very homologous, with high nucleotide
and amino acid identities (99.4–100.0% and 99.1–100.0%, respec-
tively). Lineage I of Slovenian G1 strains is more variable. Withinlineage I, VP7 nucleotide and deduced amino acid sequence identi-
ties of Slovenian strains were 90.9–100.0% and 91.6–100.0%,
respectively. Rotavirus strains from the post-vaccination period
DFig. 2 (continued)
A. Steyer et al. / Infection, Genetics and Evolution 28 (2014) 413–425 419were found mostly within lineage I; only three strains were found
in lineage II. Interestingly, pre-vaccination strains from the 2005
and 2006 period were clustered exclusively into lineage II. Inaddition to phylogenetic analysis, deduced VP7 amino acid
sequences of G1 rotavirus strains were analyzed and compared
to both vaccine G1 strains and selected Slovenian strains of
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420 A. Steyer et al. / Infection, Genetics and Evolution 28 (2014) 413–425lineages I and II. The RotaTeq sequence of the G1 VP7 strain is a
representative of the separate lineage III, very distantly related to
VP7 lineages I and II of Slovenian G1 strains (Fig. 2A and Table 1).
As shown in Fig. 3, clear changes in amino acid residues of VP7
glycoproteinwerenoted, previously shown tobeof importance for
virus neutralization. Representative rotavirus strains from the
pre-vaccination period (2005–2006), SI-GR7/05 and SI-1061/06,
were identical to the Rotarix G1 vaccine strain in all amino acid
residueswithin antigenic epitopes 7-1a and 7-1b. Only one amino
acid substitution (N147S)was observed in epitope 7-2, whichwas
identical to the RotaTeq strain and not to the Rotarix strain.
However, amino acid residues of the strains from the post-vacci-
nation period showed differences in all three antigenic epitopes.
VP7 of G4P[8] strains. In our study, G4 rotavirus strainswere the
most homologous in terms of the molecular characteristics of the
VP7 and VP8⁄ fragment of genome segments. All G4 strains were
grouped together in VP7 lineage I, sublineage Ib, with 98.4–
100.0% nucleotide sequence identity (Fig. 2C). RotaTeq G4 vac-
cine strain is slightly different to Slovenian G4 strains, with
94.2–94.8% of VP7 nucleotide and 95.3–96.2% of amino acid iden-
tity (Table 1). Aligning theaminoacid residuesof theVP7antigenic
epitopes to the RotaTeq vaccine strain, at least four differences
were noted, at positions 130, 211, 143 and 145, distributed in all
three structurally deﬁned antigenic epitopes 7-1a, 7-1b and 7-2.
Only strains SI-R326/08 and SI-951/09 had additional substitu-
tions, at positions 238 and 190, respectively (Fig. 3).
VP7 of G9P[8] strains. G9 rotavirus strains were grouped into
VP7 lineage III but forming two clusters (Fig. 2D). Both Slovenian
(SVN) major and minor G9 VP7 clusters contain rotavirus strains
from the pre- and post-vaccination period. Nucleotide sequence
identities within the clusters were 97.2–100% and between clus-
ters 96.5–98.6%. The VP7 genome segment of G9P[8] strains was
compared to the strains SI1791 and SI1804 detected in 2001 in
Slovenia (Steyer et al., 2005). Identities of these two strains to
other Slovenian G9 strains ranged between 97.1–98.4% for nucle-
otide and 97.1–99.5% for amino acid sequences. Within the anti-
genic epitopes, a few changes, including positions 100, 148 and
211, were noted comparing 2001 strains to the strains from
2005 to 2012 (Fig. 3).
VP8⁄ of G1P[8], G4P[8] and G9P[8] strains. Slovenian strains
with the P[8] VP4 genotype are grouped for the most part in
P[8] lineage III in the phylogenetic analysis (Fig. 4A). G1, G4
and G9 genotype strains were found in this lineage. A small
group of analyzed strains was also found in lineage I, together
with the Rotarix G1P[8] vaccine strain. Interestingly, all of them
are of G1P[8] genotype combination and the majority of them
were detected in the pre-vaccination period. Only three of them
were from the 2009/10 season. The same clustering was
observed in G1 VP7 phylogenetics. Similarly to VP7, Slovenian
rotavirus strains within VP8⁄ lineage I were very homologous,
sharing 99.5–100.0% nucleotide and 99.3–100.0% amino acid
identities, and 97.5% of nucleotide and 98.0–98.6% of amino acid
identities with the vaccine Rotarix strain. The variability within
lineage III was much higher, ranging from 84.2 to 100.0% of
nucleotide identity (84.0–100.0% amino acid) (Table 1). The high
similarity of VP8⁄ lineage I rotavirus strains to the Rotarix vac-
cine strain was also reﬂected in the antigenic epitopes, in which
only one difference at position 113 (region 8–3) was observed
between them. In contrast, Slovenian VP8⁄ strains within lineage
III were more closely related to RotaTeq than to the Rotarix
vaccine strain (Fig. 5).
VP7 and VP8⁄ of G2P[4] strains. All analyzed G2 rotavirus
strains were clustered in VP7 lineage IV, as shown by the phylo-
genetic analysis (Fig. 2B). They share only 92.8–93.9% of nucleo-
tide and 94.6–96.1% of amino acid identity with the vaccine
RotaTeq G2 rotavirus strain, which is found in lineage II. Within
7-1a 7-1b 7-2
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Rotarix G1P[8] T T N G E W K D Q S V V D K Q N V D N T K D Q N L S M N G
Rotateq G1P[8] . . . . D . . . . . . . . . . . . . . . . . . S . . . . .
SI-GR7/05 . . . . . . . . . . . . . - . . . . . . . . . S . . . . .
SI-1061/06 . . . . . . . . . . . . . - . . . . . . . . . S . . . . .
SI-2158/07 . . S . . . . . . N . . . - . . T . . . . . . . . . T . .
SI-R41/07 . . S . . . . . . N . . . R . . . . . . . . . . . . T . .
SI-R98/07 . N S . . . . . . N . . . - . . . . . . . . . . . . T . .
SI-R173/07 . . S . . . . . . N . . . - . . . . . . . . . . . . T . .
SI-798/08 . . S . . . . . . N . . . - . . T . . . . . . . . . T . .
SI-2539/08 . N S . . . . . . N . . . - . . . . . . . . . . . . T D .
SI-R190/09 . . S . . . . . . N . . . - . . . . . . . . . . . . T . .
SI-959/09 . . . . . . . . . . . . . - . . . . . . . . . S . . I . .
SI-739/10 . . S . . . . . . N . . . - . . T . . . . . . H . . T . .
SI-R65/11 . . S . . . . . . N . . . - . . . . . . . . . . . . T . .
SI-17/11 . . S . . . . . . N . I . - . . T . . . . . . . . . T . .
SI-257/12 . . S . . . . . . N . . . - . . . . . . . . . . . L T . .
SI-R107/12 . . S . . . . . . N . . . - . . T . . . . . . . . . T . .
Rotateq G2P[5] A N S D E W E N Q D T M N K Q D V S N S R D N T S D I S G
SI-3259/07 T . . N . . . . . . . . . - . . . D . . . . . . . . . . .
SI-R266/07 T . . N . . . . . . . . . - . . . D . N . . . . . . . . .
SI-1791/08 T . . N . . . . . . . . . - . . . D . N . . . . . . . . .
SI-1733/08 T . . N . . . . . . . . . - . . . D . . . . . . . . . . .
SI-442/09 T . . N . . . . . . . . . - . . . D . . . . . . . . . . .
SI-1928/10 T . . N . . . . . . . . . - . . . D . . . . . . . . . . .
SI-R119/11 T . . N . . . . . . . . . - . . . D . . . . . . . . . . .
SI-197/12 T . . N . . . . . . . . . - . . . D . . . . . . . . . . .
Rotateq G4P[5] S T S T E W K D Q N L I D K Q D T A D T R A S G E S T S G
SI-MB2/05 . . . . . . . . . . . . E - . N . . . . K T . . . . . . .
SI-MB35/06 . . . . . . . . . . . . E - . N . . . . K T . . . . . . .
SI-R190/07 . . . . . . . . . . . . E - . N . . . . K T . . . . . . .
SI-R326/08 . . . . . . . . . . . . E - . N . . E . K T . . . . . . .
SI-R13/08 . . . . . . . . . . . . E - . N . . . . K T . . . . . . .
SI-R202/09 . . . . . . . . . . . . E - . N . . . . K T . . . . . . .
SI-951/09 . . . . . . . . . . . . E - . N . . . . K T . . . L . . .
SI-R175/10 . . . . . . . . . . . . E - . N . . . . K T . . . . . . .
SI-R120/11 . . . . . . . . . . . . E - . N . . . . K T . . . . . . .
SI-724/12 . . . . . . . . . . . . E - . N . . . . K T . . . . . . .
SI1791/01 SVN G9 T T G T E W K D Q D A I D N Q N T A D N K D S T L S E S G
SI1804/01 . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
SI-MB44/05 . . . . . . . . . . . . . - . . . . . . . . . . V . . . .
SI-MB39/05 . . . . . . . . . . . . . - . . . . . . . . . . . . . . .
SI-761/06 . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
SI-16/08 . . . . . . . . . . . . . - . . . . . . . . . . . . . . .
SI-392/11 . . . . . . . . . . . . . - . S . . . . . . . . . . . . .
SI-1990/12 . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
SI-1082/12 . . . . . . . N . . . . . . . . . . . . . . . . . . . . .
Fig. 3. Deduced amino acid sequence in the antigenic epitopes of the VP7 glycoprotein. At position 291 the information on amino acid residue is missing in most of the
sequences presented due to the short nucleotide sequence (marked as (-)).
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95.5–100.0% and 97.3–100.0%, respectively (Table 1). All of the
analyzed strains had three differences in neutralization epitopes
in comparison to the vaccine G2 RotaTeq strain (Fig. 3), two of
them within the antigenic epitope 7-1a (A87T and D96 N) and
one within the antigenic epitope 7-1b (S213D). Within lineage IV
of the VP7 phylogenetic analysis, four strains (SI-1791/08, SI-
R266/07, SI-2287/08, SI-2321/08) were grouped separately and
all of them also express an additional amino acid difference within
the antigenic epitope 7-1b (S242N) (Figs. 2B, 3). These four strains
were also grouped separately in the VP8⁄ phylogenetic analysis
and present a slightly different pattern of amino acid residues in
the antigenic epitopes of VP8⁄, with one amino acid difference
from all other Slovenian G2P[8] strains (VP8⁄ S113I) (Fig. 5).
4. Discussion
Many studies have been published since the introduction of
rotavirus vaccines, reporting rotavirus molecular epidemiology inthe post-vaccination period. These reports were highly encourag-
ing, especially from countries with a general vaccination strategy,
where vaccination coverage within a few years exceeded 80 or
90% of children eligible for vaccination. At this time, it became
clear that the rotavirus vaccine was achieving its primary goal of
signiﬁcantly decreasing the incidence of rotavirus gastroenteritis
and severe cases of diarrhea. In Europe, a few countries introduced
rotavirus vaccination with full or partial reimbursement of the vac-
cine cost and have a very high vaccination coverage. This is the
case in Finland, Belgium and Austria. In Finland, Rotarix was
available from May 2006, RotaTeq a year later and by 2009, vac-
cination coverage had reached 35% of the vaccine eligible popula-
tion, rising to 96% after the introduction of universal vaccination
exclusively with RotaTeq in 2009 (Rasanen et al., 2011; Vesikari
et al., 2013). Severe rotavirus gastroenteritis with hospitalization
was prevented by vaccine in 92.1% of vaccine eligible children
and was reduced by 78% in children <16 years. Despite the high
vaccination coverage, no signiﬁcant changes in rotavirus genotypes
was observed to be connected directly to the high selective
AFig. 4. Phylogenetic analysis of the VP4 (VP8⁄ fragment) nucleotide sequence of (A)
genotype G1P[8], G4P[8], G9P[8] Slovenian rotavirus strains and (B) genotype
G2P[4] Slovenian strains with representative strains obtained from GenBank.
Neighbor-joining phylogenetic trees were constructed with the Mega 5.2 software
package, using the Kimura-2 parameter method with bootstrapping of 1000
replicates. SVN – a unique 3-letter country code for Slovenia.
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detailed molecular analysis of circulating strains during the period
of Rotarix use, a shift of the P[8] lineage, with multiple changes at
the dominant antigenic epitopes, was observed, which might be
connected to the use of Rotarix vaccine with up to 30% vaccine
coverage at that time (Hemming and Vesikari, 2013). In Belgium,
with an average vaccination coverage of 88.5% with Rotarix vac-
cine (Zeller et al., 2010), a signiﬁcantly higher relative prevalence
of G2P[4] was observed in vaccinated children compared to unvac-
cinated (Matthijnssens et al., 2012). Similarly to Belgian data, some
other research groups have also reported an apparently higher
prevalence of G2P[4] in a population with high Rotarix vaccine
coverage (Carvalho-Costa et al., 2009; Kirkwood et al., 2011;
Paulke-Korinek et al., 2013). In countries or regions with high Rota-
Teq vaccine coverage, a higher prevalence of G3P[8] was reported.
This phenomenon was observed in Australia and USA but there is
as yet no clear explanation of this shift (Hull et al., 2011;
Kirkwood et al., 2011; Matthijnssens et al., 2012). Although a slight
increase/emergence of G3P[8] was noted in Slovenia in 2012, it is
not likely that this was due to the use of RotaTeq vaccine, since
the coverage is too low to support such a conclusion. The vaccina-
tion coverage data for Slovenia includes both vaccines, suggesting
that RotaTeq vaccinated children are only part of it, minimizing
the possible effect as it was observed in the regions with high vac-
cination coverage exclusively with RotaTeq.
Despite the low vaccination coverage in Slovenia, it is important
to follow the molecular epidemiology of rotaviruses. Vaccination
coverage has been just below a quarter of eligible children in the
last three years and a slight trend of decrease is observed. Since
vaccination is on a voluntary basis, not covered by health insur-
ance, this percentage can be expected to remain at or below the
current level. Vaccine coverage in Slovenia is too low to conﬁrm
indisputably vaccine derived changes in the incidence or preva-
lence of rotavirus genotypes but some changes can be interpreted
on the basis of country-speciﬁc data from countries with high vac-
cination coverage. Changes that were observed after vaccine intro-
duction might thus be partially connected to selective vaccine
pressure. The ﬁrst change observed in the post-vaccination era
was a ﬂuctuation of rotavirus genotypes. The steep drop of
G1P[8] prevalence from 74.1% in 2007/08 to 8.7% in 2010/11 may
have been connected to vaccine introduction (Fig. 1A). Phyloge-
netic analysis of VP7 and VP8⁄ genes supports this hypothesis,
since rotavirus strains from the period before vaccination were
grouped into the same lineage as the Rotarix vaccine strain in
both the VP7 gene and VP8⁄ gene fragment (»Rotarix lineage«)
(Figs. 2A and 4A). Although slight differences compared to the
Rotarix vaccine strain were observed, the antigenic epitopes of
rotavirus strains before vaccination were almost identical to the
Rotarix vaccine strain. Only one amino acid difference was
observed within the antigenic epitopes of Slovenian pre-vaccina-
tion G1P[8] strains compared to the Rotarix vaccine strain in both
VP7 and VP8⁄ regions (Fig. 3). Starting from the 2007/08 season,
the »Rotarix lineages combination« (VP7 G1 lineage II and P[8]
VP8⁄ lineage I) was detected in a minority of the G1P[8] strains
analyzed (only three out of 25). It is difﬁcult to understand
whether such a shift in G1P[8] lineages is linked to the introduc-
tion of the vaccine, even at low or very low coverage, however sim-
ilar patterns of lineage substitutions were observed in Belgium and
Finland. In Belgium, Rotarix is the most used vaccine, with high
vaccine coverage, 88.5%. After the introduction of the Rotarix vac-
cine, a shift was observed in the G1P[8] lineage, an increasing
occurrence of lineage III being less related to the vaccine strain
(Zeller et al., 2012). Similarly, Rotarix was used in Finland from
2006 to 2008, with vaccine coverage of up to 29%, very similar to
the Slovenian data. After the introduction of the Rotarix vaccine,
the majority of G1P[8] strains were not in lineage I, more related
BFig. 4 (continued)
8-1 8-2 8-3 8-4
10
0
14
6
14
8
15
0
18
8
19
0
19
2
19
3
19
4
19
5
19
6
18
0
18
3
11
3
11
4
11
5
11
6
12
5
13
1
13
2
13
3
13
5 87 88 89
Rotarix_G1P[8] D S S N S S A N L N N E R N P V D S S N D N N T N
RotaTeq_P[8] . . . . . N . . . . D . . . . . . N R . . D . . .
G1 SI-R13/09 . . . . . . . . . . . . . T . . . . . . . . . . .
G1 SI-1061/06 . . . . . . . . . . . . . T . . . . . . . . . . .
G1 SI-R369/08 . G . . . N . . . D G . . . . . . N R . . D . . .
G4 SI-R326/08 . G . . . N . . . D G . . . . . . N R . . D . . .
G4 SI-R175/10 . G . . . N . . . D G . . . . . . N R . . D . . .
G4 SI-R120/11 . G . . . N . . . D G . . . . . . N R . . D . . .
G1 SI-R8/12 . G . . . N . . . D G . . . . . . N R . . D . . .
G4 SI-R3/10 . G . . . N . . . D G . . . . . . N R . . D . . .
G4 SI-MB39/05 . G . . . N . . . D G . . . . . . N R . . D . . .
G9 SI-600/10 . G . . . N . . . D G . . . . . . N R . . D . . .
G9 SI-392/11 . G . . . N . . . D G . . . . . . N R . . D . . .
G9 SI-R65/10 . G . . . N T . . D G . . . . . . N R . . D . . .
G4 SI-R202/09 . G . . . N T . . D G . . . . . . N R . . D . . .
G4 SI-951/09 . G . . . N T . . D G . . . . . . N R . . D . . .
G9 SI-97/10 . G . . . N T . . D G . . . . . . N R . . D . . .
G4 SI-R26/09 . G . . . N T . . D G . . . . . . N R . . D . . .
G4 SI-724/12 . G . . . N T . . D G . . . . . . N R . . D . . .
G4 SI-236/09 . G G . . N T . . D G . . . . . . N R . . D . . .
G1 SI-2935/11 . G . . . N . . . D G . . . . . . N G . . D . . .
G9 SI-MB32/05 . . . . . N . . . D G . . . . . . N R . . D . . .
G9 SI-1598/08 . G . . . N . D . D G . . . . . . N R . . D . . .
G1 SI-1288/12 . G . . . N . . . . G . . . . . . N R . . D . . .
G1 SI-R173/07 . G . . . N . . . . G . . D . . . N R . . D . . .
G4 SI-R8/07 . G . . . N . . . . G . . D . . . N R . . D . . .
G9 SI-713/06 . G . . . N . . . . G . . D . . . N R . . D . . .
G9 SI-16/08 . G . . . N . . . . G . . D . . . N R . . D . . .
G9 SI-900/06 . G . S . N . . . . G . . D . . . N R . . D . . .
G1 SI-R41/07 . G . . . N T . . . G . . D . . . N R . . D . . .
G1 SI-2539/08 . G N S G N S D . T S . G D . . . . R . . . . . .
G2 P[4] SI-R341/08 . . . S . N . D . . . . . S Q T N N E . S D . . D
G2 P[4] SI-R254/07 . G . S . N . D . . . . . S Q T N N E . S D . . D
G2 P[4] SI-2247/11 . G . S . N . D . . . . . S Q T N N E . S D . . D
G2 P[4] SI-2321/08 . G . S . N . D . . . . . I Q T N N E . S D . . D
Fig. 5. Deduced amino acid sequence in the antigenic epitopes of the VP8⁄ fragment of the VP4 protein.
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2013). A change in VP8⁄ sublineage has been temporally correlated
to the use of Rotarix in Finland (Hemming and Vesikari, 2013).
It is difﬁcult to discriminate whether the increase of G2P[4] in
the 2010/11 season was due to a natural ﬂuctuation of genotype
prevalence or to the effect of vaccination. However, in the neigh-
boring country, Austria, where the Rotarix vaccine is mainly used
with a vaccine coverage of up to 84%, though the general preva-
lence of rotavirus genotypes is not known, G2P[4] genotype was
mainly recorded in vaccination breakthrough (Paulke-Korinek
et al., 2013). The authors reported that according to the EuroRota-
Net database, the general prevalence of the G2P[4] genotype in
Austria rose to as high as 73% after high vaccination coverage
was reached (Paulke-Korinek et al., 2013).
No differences for genotype G4 and G9 strains were observed
throughout the study period in terms of VP7 and VP8⁄ molecular
characteristics. Rotavirus G4 genotype strains were very homolo-
gous within the same sub-lineage Ib (Fig. 2C). It is not yet possible
to draw conclusions from our data about the variation in G4 geno-
type prevalence during the study period. According to the phyloge-
netic analysis and antigenic epitopes, no speciﬁc clustering of G4
strains based on the year of detection was observed, in either
VP7 or VP4 (VP8⁄ fragment) genome segments. However, in a study
of G4 strains from archived samples in a district area of Washing-
ton DC, co-circulation of different genetic variants within the
deﬁned time-frame was noted (McDonald et al., 2011). Whole gen-
ome analysis was performed in this study, elucidating genetic var-
iability with possible genome re-assortment. The G4 genotype
breakthrough in Slovenia appears to have happened for reasons
other than variability within the VP7 and VP8⁄. Detailed whole
genome analysis could be performed in the future to better charac-
terize G4 strains circulating in the pre- and post-vaccination per-
iod. However, to the best of our knowledge, no study from
countries or areas with high vaccination coverage have reported
an increased prevalence of G4P[8] in unvaccinated or vaccinated
children. No hint of vaccine derived changes in VP7 or VP8⁄ were
observed in G9 rotavirus strains either. In VP7, all G9 strains were
found within lineage III, forming two clusters. Most of the strains
were grouped in the SVN-major cluster. No speciﬁc pattern was
observed in terms of the year of isolation or antigenic epitope dif-
ferences between the two clusters, suggesting that genetic vari-
ances were located outside the antigenic epitopes. Since the
same clustering of rotavirus G9 genotypes was also observed in
the VP8⁄ analysis, it is obvious that two variants of G9 rotavirus
strains were circulating in Slovenia, with minor genetic changes
during the study period.
Our data do not prove directly the inﬂuence of rotavirus vaccine
on rotavirus strain diversity but provide additional post-marketing
data for rotavirus vaccines in a country with low vaccination cov-
erage. The inﬂuence of rotavirus vaccine in a similar, low vaccine
coverage community was already shown in a study in Greece
(Trimis et al., 2011). The vaccine coverage was reported to be lower
than 30% but, according to hospital based data, a signiﬁcant
reduction of rotavirus gastroenteritis cases and the incidence of
rotavirus gastroenteritis was observed after introduction of the
vaccine. However, only minor changes in rotavirus genotype prev-
alence were observed, probably not connected to vaccine introduc-
tion. Although rotavirus vaccination coverage in Slovenia is low,
presented data on rotavirus incidence and rotavirus hospitalization
incidence among children 0–6 years appear to decline in the last
few seasons (Fig. 1B). In the post-vaccine period, including the four
rotavirus seasons 2009/10 to 2012/13 both calculated incidences
remained at lower level than observed in the pre-vaccination per-
iod, despite of the genotype variability. This indicates that rotavi-
rus vaccine in Slovenia might have an effect on the reduction of
rotavirus disease burden. According to the data from our study, itis also highly possible that a selective inﬂuence of vaccination
resulted in a changed molecular proﬁle of circulating G1P[8] rota-
virus strains.
Continuous monitoring of rotavirus genotypes is needed in the
future to conﬁrm the impact of even a low vaccination rate on rota-
virus strain diversity. In addition, detailed molecular analysis of
VP7 and VP4 genome segments should be performed regularly to
track strain diversity and changed patterns of strains with altered
antigenic epitopes. All these studies of antigenic epitope altera-
tions based on deduced amino acid sequences should be further
evaluated with cross-neutralization studies in order to gain real
information on possible escape mutants in the future.
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